> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Positive Results for Setrusumab in Bone Disease
- URL: https://www.fdaweb.com/positive-results-for-setrusumab-in-bone-disease/
- Published: 2024-06-12T12:00:00.000Z
- Updated: 2026-09-14T14:33:06.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157165

Ultragenyx Pharmaceutical and Mereo BioPharma say there were positive results in the Phase 2 portion of the Phase 2/3 Orbit study of setrusumab in patients with the complex bone and tissue disease osteogenesis imperfecta (OI). A [statement](https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-and-mereo-biopharma-announce-new-phase-2-data-phase?ref=fdaweb.com) from the companies says treatment with setrusumab continued to significantly reduce the incidence of fractures in patients with OI with at least 14 months of follow-up. “Treatment with setrusumab also resulted in ongoing and meaningful improvements in lumbar spine bone mineral density at month 12 without evidence of plateau,” the statement says.

Setrusumab is described as a fully human monoclonal antibody that inhibits sclerostin, a negative regulator of bone formation.